Business Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100000P02
Share Class Description:
SZSE:002399: Class ACompare
Compare
Traded in other countries / regions
002399.China09989.Hong KongSHEZF.USA IPO Date
2010-05-06Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.41 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.47 | |||||
| Debt-to-EBITDA | -7.89 | |||||
| Interest Coverage | 2.87 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.74 | |||||
| Beneish M-Score | -2.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -2 | |||||
| 3-Year FCF Growth Rate | 37.2 | |||||
| 3-Year Book Growth Rate | 1 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.4 | |||||
| 9-Day RSI | 64.66 | |||||
| 14-Day RSI | 59.79 | |||||
| 6-1 Month Momentum % | -26.52 | |||||
| 12-1 Month Momentum % | -31.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.13 | |||||
| Quick Ratio | 0.79 | |||||
| Cash Ratio | 0.45 | |||||
| Days Inventory | 740.85 | |||||
| Days Sales Outstanding | 89.52 | |||||
| Days Payable | 36.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.09 | |||||
| Dividend Payout Ratio | 2.94 | |||||
| 3-Year Dividend Growth Rate | -17.8 | |||||
| Forward Dividend Yield % | 1.09 | |||||
| 5-Year Yield-on-Cost % | 1.2 | |||||
| Shareholder Yield % | 7.22 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 33.06 | |||||
| Operating Margin % | 11.75 | |||||
| Net Margin % | -14.38 | |||||
| FCF Margin % | -0.86 | |||||
| ROE % | -6.38 | |||||
| ROA % | -3.86 | |||||
| ROIC % | 3.34 | |||||
| ROC (Joel Greenblatt) % | -6.91 | |||||
| ROCE % | -4.68 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio without NRI | 271.18 | |||||
| Shiller PE Ratio | 24.92 | |||||
| PS Ratio | 2.48 | |||||
| PB Ratio | 1.14 | |||||
| Price-to-Tangible-Book | 1.49 | |||||
| Price-to-Operating-Cash-Flow | 34.23 | |||||
| EV-to-EBIT | -21.82 | |||||
| EV-to-EBITDA | -21.82 | |||||
| EV-to-Revenue | 2.82 | |||||
| EV-to-FCF | -323.24 | |||||
| Price-to-Projected-FCF | 2.11 | |||||
| Price-to-Median-PS-Value | 0.4 | |||||
| Price-to-Graham-Number | 4.23 | |||||
| Price-to-Net-Current-Asset-Value | 4.08 | |||||
| Earnings Yield (Greenblatt) % | -4.58 | |||||
| FCF Yield % | -0.38 | |||||
| Forward Rate of Return (Yacktman) % | -21.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shenzhen Hepalink Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 5,445.573 | ||
| EPS (TTM) (Â¥) | -0.533 | ||
| Beta | 1.51 | ||
| Volatility % | 35.06 | ||
| 14-Day RSI | 59.79 | ||
| 14-Day ATR (Â¥) | 0.318795 | ||
| 20-Day SMA (Â¥) | 8.813 | ||
| 12-1 Month Momentum % | -31.08 | ||
| 52-Week Range (Â¥) | 6.89 - 13 | ||
| Shares Outstanding (Mil) | 1,467.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shenzhen Hepalink Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shenzhen Hepalink Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shenzhen Hepalink Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Shenzhen Hepalink Pharmaceutical Group Co Ltd(SZSE:002399)'s stock price today?
The current price of SZSE:002399 is ¥9.22. The 52 week high of SZSE:002399 is ¥13.00 and 52 week low is ¥6.89.
When is next earnings date of Shenzhen Hepalink Pharmaceutical Group Co Ltd(SZSE:002399)?
The next earnings date of Shenzhen Hepalink Pharmaceutical Group Co Ltd(SZSE:002399) is .
Does Shenzhen Hepalink Pharmaceutical Group Co Ltd(SZSE:002399) pay dividends? If so, how much?
The Dividend Yield %  of Shenzhen Hepalink Pharmaceutical Group Co Ltd(SZSE:002399) is 1.09% (As of Today), Highest Dividend Payout Ratio of Shenzhen Hepalink Pharmaceutical Group Co Ltd(SZSE:002399) was 7.58. The lowest was 0.07. And the median was 0.44. The  Forward Dividend Yield % of Shenzhen Hepalink Pharmaceutical Group Co Ltd(SZSE:002399) is 1.09%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers